RxDoctor Payments DataLook up a doctor →

Erika Vance, APRN

Family · Jonesboro, ARNPI 1366816670

Payments from drug & device makers

$10,231in general payments, 2019–2025

Across 694 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$923
  • Lilly USA, LLC$807
  • Novo Nordisk$797
  • GSK$651
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,02298%
  • Education$2092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,231 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$102,127
Medicare patients
411
Services billed
10,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$54,222
OzempicSemaglutide42$48,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,512
JanuviaSitagliptin Phosphate42$31,434
EliquisApixaban32$23,361
JardianceEmpagliflozin20$20,944
XareltoRivaroxaban20$15,389
LinzessLinaclotide15$15,179
EntrestoSacubitril/Valsartan17$8,495
Tresiba Flextouch U-200Insulin Degludec12$7,017
Breo ElliptaFluticasone/Vilanterol13$6,250
Trijardy XrEmpaglifloz/Linaglip/Metformin11$5,945
Albuterol Sulfate HfaAlbuterol Sulfate75$2,211
Potassium Chloride153$2,194
Ranolazine ErRanolazine27$2,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$807$54,22249 claims
Novo NordiskOzempic$797$48,57642 claims
GSKTrelegy Ellipta, Breo Ellipta$651$37,76257 claims
MerckJanuvia$339$31,43442 claims
Boehringer IngelheimJardiance, Trijardy Xr$296$26,88931 claims
PfizerEliquis$1,096$23,36132 claims
AbbVieLinzess, Synthroid$1,292$16,60029 claims
Johnson & JohnsonXarelto$46$15,38920 claims
NovartisEntresto$325$8,49517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →